Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
The European Journal of Health Economics
Published in: The European Journal of Health Economics 4/2012

01-08-2012 | Original Paper

A proposed model for economic evaluations of major depressive disorder

Authors: Hossein Haji Ali Afzali, Jonathan Karnon, Jodi Gray

Published in: The European Journal of Health Economics | Issue 4/2012

Login to get access

Abstract

In countries like UK and Australia, the comparability of model-based analyses is an essential aspect of reimbursement decisions for new pharmaceuticals, medical services and technologies. Within disease areas, the use of models with alternative structures, type of modelling techniques and/or data sources for common parameters reduces the comparability of evaluations of alternative technologies for the same condition. The aim of this paper is to propose a decision analytic model to evaluate long-term costs and benefits of alternative management options in patients with depression. The structure of the proposed model is based on the natural history of depression and includes clinical events that are important from both clinical and economic perspectives. Considering its greater flexibility with respect to handling time, discrete event simulation (DES) is an appropriate simulation platform for modelling studies of depression. We argue that the proposed model can be used as a reference model in model-based studies of depression improving the quality and comparability of studies.
Literature
1.
Ostin, T.B., Ayuso-Mateos, J.L., Mathers, C., et al.: Global burden of depressive disorders in the year 2000. Br. J. Psychiatry 184, 386–392 (2004)CrossRef
2.
World Health Organisation: The World Health Report 2001. Mental Health: New Understanding New Hope. WHO, Geneva (2002)
3.
Guzzetta, F., Tondo, L., Centorrino, F., et al.: Lithium treatment reduces suicide risk in recurrent major depressive disorder. J. Clin. Psychiatry 68, 380–383 (2007)CrossRefPubMed
4.
Dumais, A., Lesage, A.D., Alda, M., Rouleau, G., Dumont, M., Chawky, N., Roy, M., Mann, J.J., Benkelfat, C., Turecki, G.: Risk factors for suicide completion in major depression: a case-control study of impulsive and aggressive behaviors in men. Am. J. Psychiatry 162, 2116–2124 (2005)CrossRefPubMed
5.
Wells, K.B., Stewart, A., Hays, R.D., Burnam, M.A., Rogers, W., Daniels, M., Berry, S., Greenfield, S., Ware, J.: The functioning and well-being of depressed patients. Results from the medical outcomes study. JAMA 262, 914–919 (1989)CrossRefPubMed
6.
Lustman, P.J., Anderson, R.J., Freedland, K.E., et al.: Depression and poor glycemic control: a meta-analytic review of the literature. Diabetes Care 23, 934–942 (2000)CrossRefPubMed
7.
Henry, J.A., Rivas, C.A.: Constraints on antidepressant prescribing and principles of cost-effective antidepressant use. Part 1: depression and its treatment. Pharmacoeconomics 11, 419–443 (1997)CrossRefPubMed
8.
Kaplan, W., Laing, R.: Priority Medicines for Europe and the World. WHO, Geneva (2004)
9.
Pharmaceutical benefits advisory committee: Guidelines for Preparing Submissions to the Pharmaceutical Benefits Advisory Committee. Pharmaceutical Benefits Advisory Committee, Canberra (2008)
10.
Buxton, M.J., Drummond, M.F., Van Hout, B.A., et al.: Modelling in economic evaluation: an avoidable fact of life. Health Econ. 6, 217–227 (1997)CrossRefPubMed
11.
Campbell, H., Briggs, A., Buxton, M., et al.: The credibility of health economic models for health policy decision-making: the case of population screening for abdominal aortic aneurysm. J. Health Serv. Res. Policy 12, 11–17 (2007)CrossRefPubMed
12.
Consensus Conference on Guidelines on Economic Modelling in Health Technology Assessment: Decision analytic modelling in the economic evaluation of health technologies: a consensus statement. Pharmacoeconomics 17, 443–444 (2000)CrossRef
13.
Karnon, J., Brown, J.: Selecting a decision model for economic evaluation: a case study and review. Health Care Manag. Sci. 1, 133–140 (1998)CrossRefPubMed
14.
Nuijten, M.J.: The selection of data sources for use in modelling studies. Phramacoeconomics 13, 305–316 (1998)CrossRef
15.
Sobocki, P.: Health Economics of Depression. Karolinska Institute, Stockholm (2006)
16.
Hylan, T., Buesching, D.P., Tollefson, G.D.: Health economic evaluations of antidepressants: a review. Depress Anxiety 7, 53–64 (1998)CrossRefPubMed
17.
Jones, M.T., Cockrum, P.C.: A critical review of published economic modelling studies in depression. Pharmacoeconomics 17, 555–583 (2000)CrossRefPubMed
18.
Frank, L., Revicki, D.A., Sorensen, S.V., et al.: The economics of selective serotonin reuptake inhibitors in depression: a critical review. CNS Drugs 15, 59–83 (2001)CrossRefPubMed
19.
Iqbal, S.U., Prashker, M.: Pharmacoeconomic evaluation of antidepressants. A critical appraisal of methods. Pharmacoeconomics 23, 595–606 (2005)CrossRefPubMed
20.
Haji Ali Afzali, H., Karnon, J., Gray, J.: A critical review of model-based economic studies of depression: modelling techniques, model structure and data sources. Pharmacoeconomics (In press)
21.
Harris, A., Buxton, M., O’Brien, B., et al.: Using economic evidence in reimbursement decisions for heath technologies: experience of 4 countries. Expert Rev Pharmacoecon Outcomes Res 1, 7–12 (2001)CrossRefPubMed
22.
Nordstrom, G., Despiegel, N., Marteau, F., et al.: Cost effectiveness of escitalopram versus SNRIs in second-step treatment of major depressive disorder in Sweden. J. Med. Econ. 13, 516–526 (2010)CrossRefPubMed
23.
Sado, M., Knapp, M., Yamauchi, K., et al.: Cost-effectiveness of combination therapy versus antidepressant therapy for management of depression in Japan. Aust. N. Z. J. Psychiatry 43, 539–547 (2009)CrossRefPubMed
24.
Simon, J., Pilling, S., Burbeck, R., et al.: Treatment options in moderate and severe depression: decision analysis supporting a clinical guideline. Br. J. Psychiatry 189, 494–501 (2006)CrossRefPubMed
25.
Sullivan, P.W., Valuck, R., Saseen, J., et al.: A comparison of the direct costs and cost effectiveness of serotonin reuptake inhibitors and associated adverse drug reactions. CNS Drugs 18, 911–932 (2004)CrossRefPubMed
26.
François, C., Sintonen, H., Toumi, M.: Introduction of escitalopram, a new SSRI in Finland: comparison of cost-effectiveness between the other SSRIs and SNRI for the treatment of depression and estimation of the budgetary impact. J. Med. Econ. 5, 91–107 (2002)CrossRef
27.
Lenox-Smith, A., Greenstreet, L., Burslem, K., et al.: Cost effectiveness of venlafaxine compared with generic fluoxetine or generic amitriptyline in major depressive disorder in the UK. Clin. Drug Investig. 29, 173–184 (2009)CrossRefPubMed
28.
Trivedi, M.H., Wan, G.J., Mallick, R., et al.: Cost and effectiveness of venlafaxine extended-release and SSRIs in the acute phase of outpatient’s treatment for major depressive disorder. J. Clin. Psychopharmacol. 24, 497–506 (2004)CrossRefPubMed
29.
Armstrong, E.P., Skrepnek, G.H., Haim Erder, M.: Cost–utility comparison of escitalopram and sertraline in the treatment of major depressive disorder. Curr. Med. Res. Opin. 23, 251–258 (2007)CrossRefPubMed
30.
Benedict, A., Arellano, J., De Cock, E., et al.: Economic evaluation of duloxetine versus serotonin selective reuptake inhibitors and venlafaxine XR in treating major depressive disorder in Scotland. J. Affect. Disord. 120, 94–104 (2010)CrossRefPubMed
31.
Armstrong, E.P., Malone, D.C., Haim Erder, M.: A Markov cost-utility analysis of escitalopram and duloxetine for the treatment of major depressive disorder. Curr. Med. Res. Opin. 24, 1115–1121 (2008)CrossRefPubMed
32.
Wang, P.S., Patrick, A., Azocar, F., et al.: The costs and benefits of enhanced depression care to employers. Arch. Gen. Psychiatry 63, 1345–1353 (2006)CrossRefPubMed
33.
Aziz, M., Mehringer, A.M., Mozurkewich, E., et al.: Cost-utility of 2 maintenance treatments for older adults with depression who responded to a course of electroconvulsive therapy: results from a decision analytic model. Can. J. Psychiatry 50, 389–397 (2005)PubMed
34.
Sobocki, P., Ekman, M., Ovanfors, A., et al.: The cost-utility of maintenance treatment with venlafaxine in patients with recurrent major depressive disorder. Int. J. Clin. Pract. 62, 623–632 (2008)CrossRefPubMed
35.
Sobocki, P., Ekman, M., Agren, H., et al.: Model to assess the cost-effectiveness of new treatments for depression. Int J Technol Assess Health Care 22, 469–477 (2006)CrossRefPubMed
36.
Kupfer, D.J.: Long-term treatment of depression. J. Clin. Psychiatry 52, 28–34 (1991)PubMed
37.
American Psychiatric Association: Practice guideline for the treatment of patients with major depressive disorder. Am. J. Psychiatry 157, 1–45 (2000)
38.
National Institute for Health and Clinical Excellence: Depression: the treatment and management of depression in adults. National Institute for Health and Clinical Excellence (2009)
39.
Miller, I.W., Keitner, G.I., Schatzberg, A.F., et al.: The treatment of chronic depression: psychosocial functioning before and after treatment with sertraline or imipramine. J. Clin. Psychiatry 59, 608–619 (1998)CrossRefPubMed
40.
Klein, D.N., Shankman, S.A., Rose, S.: Ten-year prospective follow-up study of the naturalistic course of dysthymic disorder and double depression. Am. J. Psychiatry 163, 872–880 (2006)CrossRefPubMed
41.
Satyanarayana, S., Enns, M.W., Cox, B.J., et al.: Prevalence and correlates of chronic depression in the Canadian community health survey: mental health and well-being. Can. J. Psychiatry 54, 389–398 (2009)PubMed
42.
American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, 4th edn. American Psychiatric Association, Washington D.C (1994)
43.
Klein, D.N.: Chronic depression: diagnosis and classification. Curr. Dir. Psychol. Sci. 19, 96–100 (2010)CrossRef
44.
Rowe, S.K., Rapaport, M.H.: Classification and treatment of sub-threshold depression. Curr. Opin. Psychiatry 19, 9–13 (2006)CrossRefPubMed
45.
Keller, M.B., Kleman, G.L., Lavori, P.W., et al.: Long-term outcome of episodes of major depression. JAMA 252, 788–792 (1998)CrossRef
46.
McCullough, J.P., Kornstein, S.G., McCullough, P., et al.: Differential diagnosis of chronic depressive disorders. Psychiatr. Clin. North Am. 19, 55–71 (1996)CrossRefPubMed
47.
Fineberg, H.V.: Decision trees: construction, uses, and limits. Bull. Cancer 67, 395–404 (1980)PubMed
48.
Klein, R.W., Dittus, R.S., Roberts, S.D., et al.: Simulation modelling and health care decision making. Med. Decis. Making 13, 347–354 (1993)CrossRefPubMed
49.
Hardeveld, F., Spijker, J., De Graaf, R., et al.: Prevalence and predicators of recurrence of major depressive disorder in the adult population. Acta Psychiatr. Scand. 122, 184–191 (2010)CrossRefPubMed
50.
Lewinsohn, P.M., Rohde, P., Seeley, J.R., et al.: Natural course of adolescent major depressive disorder in community sample: predicators of recurrence in young adults. Am. J. Psychiatry 157, 1584–1591 (2000)CrossRefPubMed
51.
Conradi, H.J., Jonge, P., Ormel, J.: Prediction of the three-year course of recurrent depression in primary care patients: different risk factors for different outcomes. J. Affect. Disord. 105, 267–271 (2008)CrossRefPubMed
52.
Marcus, S.M., Young, E.A., Kerber, K.B., et al.: Gender differences in depression: findings from the STAR*D study. J. Affect. Disord. 87, 141–150 (2005)CrossRefPubMed
53.
Karnon, J.: Alternative decision modelling techniques for the evaluation of health care technologies: Markov processes versus discrete event simulation. Health Econ. 12, 837–848 (2003)CrossRefPubMed
54.
Le Lay, A., Despiegel, N., Francois, C., et al.: Can discrete event simulation be of use in modelling major depression? Cost Eff. Resour. Alloc. 4, 19 (2006)CrossRefPubMed
55.
Banks, J., Carson, J.S., Nelson, B.L., et al.: Discrete Event System Simulation, 5th edn. Prentice-Hall, New Jersey (2010)
56.
Khan, A., Khan, S.R., Shankles, E.B., et al.: Relative sensitivity of the Montgomery-Asberg depression rating scale, the Hamilton depression rating scale and the clinical global impressions rating scale in antidepressant clinical trials. Int. Clin. Psychopharmacol. 17, 281–285 (2002)CrossRefPubMed
57.
Nierenberg, A., De Cecco, L.M.: Definitions of antidepressant treatment response, remission, nonresponse, partial response, and other relevant outcomes: a focus on treatment-resistant depression. J Clin Psychiatry 62, (Suppl) 5–9 (2001)
58.
Frank, E., Prien, R.F., Jarrett, R.B., et al.: Conceptualization and rationale for consensus definitions of terms in major depressive disorder. Arch. Gen. Psychiatry 48, 851–855 (1991)CrossRefPubMed
59.
Zimmerman, M., Posternak, M., Chelminski, I.: Defining remission on the Montgomery-Asberg depression rating scale. J. Clin. Psychiatry 65, 163–168 (2004)CrossRefPubMed
60.
Geddes, J.R., Carney, S.M., Davies, C., et al.: Relapse prevention with antidepressant drug treatment in depressive disorders: a systematic review. Lancet 361, 653–661 (2003)CrossRefPubMed
61.
Pliskin, J.S., Tell, E.J.: A dialysis need forecasting model: a retrospective evaluation. Med. Decis. Making 3, 489–500 (1983)CrossRefPubMed
62.
Harris, A., Bulfone, L.: Getting value for money: the Australian experience. In: Jost, T.S., (ed.) Health care Coverage Determinations: An International Comparative Study, pp. 25–56. Open University Press, Maidenhead, UK (2005)
63.
Halpern, M.T., Luce, B.R., Brown, R.E., et al.: Health and economic outcomes modelling practices: a suggested framework. Value Health 1, 131–147 (1998)CrossRefPubMed
64.
Sculpher, M., Fenwick, E., Claxton, K.: Assessing quality in decision analytic cost-effectiveness models: a suggested framework and example of application. Pharmacoeconomics 17, 461–477 (2000)CrossRefPubMed
65.
Sheldon, T.A.: Problems of using modelling in the economic evaluation of health care. Health Econ. 5, 1–11 (1996)CrossRefPubMed
66.
67.
Weinstein, M.C., O’Brien, B., Hornberger, J., et al.: Principles of good practice for decision analytic modelling in health-care evaluation: report of the ISPOR task force on good research practices—modelling studies. Value Health 6, 9–17 (2003)CrossRefPubMed
68.
Eddy, D.M., Schlessinger, L.: Validation of the Archimedes diabetes model. Diabetes Care 26, 3102–3110 (2003)CrossRefPubMed
69.
70.
Beilby, J., Marley, J., Walker, D., et al.: Effects of changes in antibiotic prescribing on patient outcomes in a community setting: a natural experiment. Clin. Infect. Dis. 34, 55–64 (2002)CrossRefPubMed
Metadata
Title
A proposed model for economic evaluations of major depressive disorder
Authors
Hossein Haji Ali Afzali
Jonathan Karnon
Jodi Gray
Publication date
01-08-2012
Publisher
Springer-Verlag
Published in
The European Journal of Health Economics / Issue 4/2012
Print ISSN: 1618-7598
Electronic ISSN: 1618-7601
DOI
https://doi.org/10.1007/s10198-011-0321-3

Other articles of this Issue 4/2012

The European Journal of Health Economics 4/2012 Go to the issue

Original Paper

On the meaningfulness of testing preference axioms in stated preference discrete choice experiments

Original Paper

Cost–effectiveness of statins revisited: lessons learned about the value of innovation

Editorial

Coping with uncertainty on health decisions: assessing new solutions

Original Paper

Cost of care for colorectal cancer in Ireland: a health care payer perspective

Original Paper

The way that you do it? An elaborate test of procedural invariance of TTO, using a choice-based design

Original Paper

In with the new: the determinants of prescribing innovation by general practitioners in Ireland